Last reviewed · How we verify

Livtencity — Competitive Intelligence Brief

Livtencity (MARIBAVIR) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Cytomegalovirus pUL97 Kinase Inhibitor [EPC]. Area: Oncology.

marketed Cytomegalovirus pUL97 Kinase Inhibitor [EPC] Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Livtencity (MARIBAVIR) — Takeda. Livtencity works by inhibiting the pUL97 kinase enzyme, which is essential for the replication of cytomegalovirus.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Livtencity TARGET MARIBAVIR Takeda marketed Cytomegalovirus pUL97 Kinase Inhibitor [EPC] 2021-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Cytomegalovirus pUL97 Kinase Inhibitor [EPC] class)

  1. Takeda · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Livtencity — Competitive Intelligence Brief. https://druglandscape.com/ci/maribavir. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: